2008 a year of consolidation for Swissmedic
This article was originally published in RAJ Devices
Executive Summary
In its annual report, Swissmedic, the Swiss therapeutic products regulatory agency, has dubbed 2008 a year of consolidation1. Following the reorganisation and restructuring efforts that caused a major upheaval for the agency until mid-2007, Swissmedic was in 2008 able to settle into its new processes and take stock of its achievements.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.